Ception Therapeutics, Inc. was a privately held biopharmaceutical company focused on the discovery and development of novel products to address areas of unmet medical need. The company's pipeline includes CINQUIL™ in clinical development for certain eosinophil-mediated conditions and an established program to discover small molecule, orally-active, anti-TNF (tumor necrosis factor) receptor agents. Cephalon acquired Ception in 2009.